CRSP
Price
$61.09
Change
+$0.33 (+0.54%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
5.53B
35 days until earnings call
NVAX
Price
$8.64
Change
-$0.02 (-0.23%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.41B
42 days until earnings call
Interact to see
Advertisement

CRSP vs NVAX

Header iconCRSP vs NVAX Comparison
Open Charts CRSP vs NVAXBanner chart's image
CRISPR Therapeutics AG
Price$61.09
Change+$0.33 (+0.54%)
Volume$17.88K
Capitalization5.53B
Novavax
Price$8.64
Change-$0.02 (-0.23%)
Volume$22.93K
Capitalization1.41B
CRSP vs NVAX Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. NVAX commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and NVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (CRSP: $60.76 vs. NVAX: $8.67)
Brand notoriety: CRSP: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 86% vs. NVAX: 55%
Market capitalization -- CRSP: $5.53B vs. NVAX: $1.41B
CRSP [@Biotechnology] is valued at $5.53B. NVAX’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 5 bearish.
  • NVAX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -0.70% price change this week, while NVAX (@Biotechnology) price change was +1.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

NVAX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.53B) has a higher market cap than NVAX($1.41B). CRSP YTD gains are higher at: 54.370 vs. NVAX (7.836). NVAX has higher annual earnings (EBITDA): 496M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. NVAX (612M). CRSP has less debt than NVAX: CRSP (215M) vs NVAX (228M). NVAX has higher revenues than CRSP: NVAX (1.08B) vs CRSP (35M).
CRSPNVAXCRSP / NVAX
Capitalization5.53B1.41B392%
EBITDA-533.5M496M-108%
Gain YTD54.3707.836694%
P/E RatioN/A3.91-
Revenue35M1.08B3%
Total Cash1.72B612M281%
Total Debt215M228M94%
FUNDAMENTALS RATINGS
CRSP vs NVAX: Fundamental Ratings
CRSP
NVAX
OUTLOOK RATING
1..100
721
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4045
P/E GROWTH RATING
1..100
7611
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (64) in the Biotechnology industry is in the same range as NVAX (82). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Price Growth Rating (40) in the Biotechnology industry is in the same range as NVAX (45). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for CRSP (76). This means that NVAX’s stock grew somewhat faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 30 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWAYX14.330.08
+0.56%
Nationwide GQG US Quality Eq Eagle
MGLRX16.800.05
+0.30%
MFS Global Real Estate R6
HEIIX13.80N/A
N/A
Hennessy Equity and Income Institutional
HGIFX59.30-0.37
-0.62%
Hartford Core Equity F
PCLCX20.20-0.22
-1.08%
PACE Large Co Growth Equity P

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-2.16%
RXRX - CRSP
68%
Closely correlated
-3.41%
BEAM - CRSP
67%
Closely correlated
-2.79%
NTLA - CRSP
62%
Loosely correlated
-1.04%
ABCL - CRSP
59%
Loosely correlated
+1.45%
PRME - CRSP
58%
Loosely correlated
+8.02%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.25%
MRNA - NVAX
50%
Loosely correlated
-2.90%
ARCT - NVAX
40%
Loosely correlated
-3.66%
BNTX - NVAX
40%
Loosely correlated
-0.46%
XNCR - NVAX
37%
Loosely correlated
-0.67%
CRSP - NVAX
36%
Loosely correlated
-2.16%
More